PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma APAC – English USA – English USA – English Japan – Japanese Korea – 한국어 USA – español USA – Deutsch

Based on promising early clinical results from PeproMene Bio’s PMB-102 Phase 1 study, they will receive $6M USD upfront plus an…

5 min read